Abstracts tagged "DMARDs"

Abstract Number: 1697 • 2018 ACR/ARHP Annual Meeting
Refractory Lupus Patients: How Frequent Do We See Them in the 21st Century?
Valeria Scaglioni¹, Marina Scolnik¹, Enrique R Soriano¹ and Guillermo J. Pons-Estel², ¹Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario. Argentina, Rosario, Argentina
Background/Purpose: management of systemic lupus erythematosus (SLE) patients is challenging because of the heterogeneity of the disease. While treatment of renal nephritis is more standardized,…
Abstract Number: 2523 • 2018 ACR/ARHP Annual Meeting
Rapid Response with Upadacitinib Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Csdmards or Bdmards
Oliver FitzGerald¹, Andrea Rubbert-Roth², Kun Chen³, Sebastian Meerwein⁴, Jose Jeffrey Enejosa³, Tim Shaw³ and Alvin F. Wells⁵, ¹St. Vincent’s Univ Hospital and Conway Inst Univ College Dublin, Dublin, Ireland, ²Kantonsspital St. Gallen, St Gallen, Switzerland, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Deutschland, Ludwigshafen, Germany, ⁵Rheum and Immunotherapy Ctr, Franklin, WI
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor selective for JAK1, demonstrated efficacy in patients (pts) with moderate to severe rheumatoid arthritis (RA) with an inadequate…
Abstract Number: 544 • 2018 ACR/ARHP Annual Meeting
Does Anti-Citrullinated Protein Antibody Status Modify Treatment Effect of Certain Biologic DMARDs?
Evo Alemao¹, Yedid Elbez², Yogesh Saini³, Sean E. Connolly¹, Aarti Rao³, Christine K Iannaccone⁴, Michael E Weinblatt⁴ and Nancy A. Shadick⁴, ¹Bristol-Myers Squibb, Princeton, NJ, ²Excelya, Boulogne-Billancourt, France, ³Mu Sigma, Bangalore, India, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Multiple therapeutic options with different mechanistic actions are available to treat patients (pts) with RA. However, selecting therapies by the characteristics of pts with…
Abstract Number: 963 • 2018 ACR/ARHP Annual Meeting
Long-Term Safety of Tofacitinib up to 9.5 Years: A Comprehensive Integrated Analysis of the RA Clinical Development Program
Stanley Cohen¹, Yoshiya Tanaka², Xavier Mariette³, Jeffrey R. Curtis⁴, Eun Bong Lee⁵, Peter Nash⁶, Kevin Winthrop⁷, Christina Charles-Schoeman⁸, Lisy Wang⁹, Connie Chen¹⁰, Kenneth Kwok¹⁰, Pinaki Biswas¹⁰, Andrea Shapiro¹¹, Ann Madsen¹⁰ and Jürgen Wollenhaupt¹², ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Paris-Sud University, Le Kremlin Bicêtre, France, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Seoul National University, Seoul, Korea, Republic of (South), ⁶University of Queensland, Brisbane, Australia, ⁷Oregon Health and Science University, Portland, OR, ⁸University of California, Los Angeles, CA, ⁹Pfizer Inc, Groton, CT, ¹⁰Pfizer Inc, New York, NY, ¹¹Pfizer Inc, Peapack, NJ, ¹²Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Here, we report the largest integrated safety analysis of tofacitinib to date…
Abstract Number: 1892 • 2018 ACR/ARHP Annual Meeting
Patient and Health System Characteristics Associated with Receipt of Disease Modifying Anti-Rheumatic Drugs in a National VA Sample
Jennifer Barton^1,2, Aldona Herrndorf³, Gabriela Schmajuk⁴, Rachel A. Matsumoto³, Linda Ganzini^2,3 and Kathleen Carlson^2,3, ¹Rheumatology, VA Portland Health Care System, Portland, OR, ²Oregon Health & Science University, Portland, OR, ³VA Portland Health Care System, Portland, OR, ⁴San Francisco VA Medical Center, San Francisco, CA
Background/Purpose: The Department of Veterans Affairs (VA) operates the largest integrated health care system in the U.S. The proportion of Veterans with RA who receive…
Abstract Number: 2541 • 2018 ACR/ARHP Annual Meeting
Impact of 12-Weeks of Upadacitinib Treatment on Individual and Composite Disease Measures in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic or Biologic Dmards
Ronald van Vollenhoven¹, Robin K. Dore², Kun Chen³, Heidi S. Camp³, Jose Jeffrey Enejosa³, Tim Shaw³, Jessica Suboticki³ and Stephen Hall⁴, ¹Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²Univ of California, Los Angeles, CA, ³AbbVie Inc., North Chicago, IL, ⁴Department of Medicine, Monash University, Cabrini Health and Emeritus Research, Malvern, Australia
Background/Purpose: Upadacitinib (UPA), an oral, JAK1-selective inhibitor, demonstrated efficacy through 12 and 24 weeks (wks) in phase 3 trials of patients (pts) with active rheumatoid…
Abstract Number: 206 • 2017 ACR/ARHP Annual Meeting
Real World IGRA Testing in Rheumatology Practice
Paul DeMarco^1,2, Megan Bishop³, Ashling Smith⁴, Herbert S. B. Baraf^1,5, Andrew Gregory DeMarco⁶, Temitope Ademola⁷, Deborah Contreras⁸, Adalisa Enriquez RMA¹, Lisa Klein¹, Kayra Perez¹, Sandra Ventura¹, Janice Whyte-Whitworth¹, Vince Calhoun¹, Theresa Bass Goldman¹ and Alan K Matsumoto^1,9, ¹The Center for Rheumatology and Bone Research, Wheaton, MD, ²Division of Rheumatology, Department of Medicine, Georgetown University School of Medicine, Washington, DC, ³Clinical Trials, The Center for Rheumatology and Bone Research, Wheaton, MD, ⁴2730 University Blvd West, Suite 306, The Center for Rheumatology and Bone Research, Wheaton, MD, ⁵Department of Medicine, George Washington University School of Medicine, Washington, DC, ⁶Department of Biochemistry and Molecular Cellular Biology, Georgetown University Department of Biochemistry and Molecular Cellular Biology, Washington, DC, ⁷The Center for Rheumatology and Bone Research, Washington, DC, ⁸2730 University Boulevard West, Suite 306, The Center for Rheumatology and Bone Research, Wheaton, MD, ⁹Department of Medicine, Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Mycobacterium tuberculosis (MTb) screening is routine for clinical trial protocols, & authorization for immunomodulators use by health insurances. Real world data is needed to…
Abstract Number: 1044 • 2017 ACR/ARHP Annual Meeting
Medical Care Costs Associated with Rheumatoid Arthritis in the US: A Meta-Analysis
Andrew Hresko¹, Tzu-Chieh Lin² and Daniel H. Solomon³, ¹Tufts Medical School, Boston, MA, ²Health Outcomes, Amgen, Thousand Oaks, CA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a morbid, mortal, and costly condition without a cure. Treatments for RA have expanded over the last two decades…
Abstract Number: 2098 • 2017 ACR/ARHP Annual Meeting
Systemic Treatment for ACUTE Anterior Uveitis ( SYNTHETIC AND BIOLOGIC DISEASE-MODIFYINGANTIRHEUMATIC DRUGS) : A Systematic Literature Review
Alejandro Gómez-Gómez¹, Estibaliz Loza², Maria P Rosario³, Gerard Espinosa⁴, Jose M Ruiz de Morales⁵, Jose M Herreras⁶, Santiago Muñoz⁷ and Miguel Cordero-Coma⁸, ¹Hospital Universitario Infanta Sofía, Madrid, Spain, ²Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ³Instituto de Salud Musculoesquelética, Madrid, Spain, ⁴Autoimmune Diseases Department. Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Complejo Asistencial Universitario de León, León, Spain, ⁶Ophthalmology, Hospital Universitario, IOBA, Valladolid, Spain, ⁷Rheumatology, Hospital Infanta Sofia, Madrid, Spain, ⁸Ophthalmology, Hospital de León. Spain, León, Spain
Background/Purpose: Acute anterior uveitis (AAU) is the most common form of uveitis. One third of AAU patients may present recurrences, some requiring systemic disease-modifying antirheumatic…
Abstract Number: 355 • 2017 ACR/ARHP Annual Meeting
Perceptions and Outcomes of Pregnancy and Lactation in Patients with Rheumatic Diseases
Brooke Mills¹, Kathryn H. Dao², Kristen Tecson², Emily Fishman³, Rachel Tate² and John J. Cush², ¹Internal Medicine, Baylor University Medical Center, Dallas, TX, ²Baylor Research Institute, Dallas, TX, ³Texas A&M HSC College of Medicine, Dallas, TX
Background/Purpose: Once diagnosed with a rheumatic disease, women often defer or avoid pregnancy or lactation, fearing adverse outcomes for their offspring or for themselves. Scant…
Abstract Number: 1100 • 2017 ACR/ARHP Annual Meeting
Communication between Inpatient and Outpatient Specialty Clinicians: Developing a Better Understanding of Patients with Rheumatoid Arthritis Who Are Admitted to the Hospital
Abraham Tacang¹, Christina Downey², Alfred Denio¹, Eric Newman³ and Lisa L. Schroeder⁴, ¹Rheumatology, Geisinger Medical Center, Danville, PA, ²Geisinger Medical Center, Danville, PA, ³Department of Rheumatology, Geisinger Medical Center, Danville, PA, ⁴Rheumatology, Geisinger Health System, Danville, PA
Background/Purpose: Effective communication is essential in caring for medically complex patients with rheumatoid arthritis (RA). Communication between clinicians becomes even more crucial when a patient…
Abstract Number: 2290 • 2017 ACR/ARHP Annual Meeting
Comparing Effectiveness of Early Initiation of Biologic Treatment for Newly Diagnosed Juvenile Idiopathic Arthritis Using a Novel Statistics Causal Inference Method Applied to Observational Data
Bin Huang¹, Esi Morgan², Chen Chen², Jinzhong Liu², Michelle Adams², Timothy Beukelman³, Hermine I. Brunner⁴ and Daniel J Lovell⁵, ¹Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵PRCSG, Cincinnati, OH
Background/Purpose: We compare the effectiveness of two approaches to treat Juvenile idiopathic arthritis (JIA): early combination of biologic and non-biologic disease modifying anti rheumatic drugs…
Abstract Number: 389 • 2017 ACR/ARHP Annual Meeting
S-110483 a New Potent EP4 Receptor Antagonist with Immunomodulatory and Analgesic Activities
Takashi Maeda¹, Toshitaka Ochiai², Toshie Nagayasu-Tanaka¹, Yuta Morisaki¹, Haruka Takizawa¹, Seiji Ishihara¹, Shigeo Kurokawa¹, Kiyoharu Ukai¹ and Masahiro Suda¹, ¹Pharmacology Department, Kaken Pharmaceutical Co., LTD, Kyoto, Japan, ²Kaken Pharmaceutical Co., LTD, Kyoto, Japan
Background/Purpose: Prostaglandin (PG) E2 is known to enhance the expansion of T helper 17 (Th17) cell population via EP4 receptor (EP4) in the early phase…
Abstract Number: 1159 • 2017 ACR/ARHP Annual Meeting
National Recommendations on the Use of Immunomodulatory Drugs in Patients with NON-Infectious NON-Malignant Anterior Uveitis
Gerard Espinosa¹, Santiago Muñoz², Jose M Ruiz de Morales³, Jose M Herreras⁴ and Miguel Cordero-Coma⁵, ¹Autoimmune Diseases Department. Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Infanta Sofia, Madrid, Spain, ³Complejo Asistencial Universitario de León, León, Spain, ⁴Ophthalmology, Hospital Universitario, IOBA, Valladolid, Spain, ⁵Ophthalmology, Hospital de León. Spain, León, Spain
Background/Purpose: Anterior uveitis (AU) is the most common pattern of uveitis, that migh lead to important ocular complications including blindness. Immunomodulatory drugs have been used…
Abstract Number: 2404 • 2017 ACR/ARHP Annual Meeting
Use of Dmards after the Diagnosis of Cancers in Patients with RA
Young Bin Joo, Yune-Jung Park, Ki-Jo Kim and Kyung-Su Park, Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea, Republic of (South)
Background/Purpose: Although there are many studies about the association of disease-modifying anti-rheumatic drugs (DMARDs) with cancers in patients with rheumatoid arthritis (RA), there are few…

« Previous Page
1
…
5
6
7
8
9
…
24
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.